BioVaxys Technology Corp. (CSE: BIOV) has adjusted the terms of its asset acquisition deal with Horizon Technology Finance Corporation, reducing the capital-raise milestone for the DPX™ immune educating platform originally developed by Canadian biotech IMV Inc.

Under the original Asset Purchase Agreement (APA) dated February 11, 2024, BioVaxys was required to raise $10 million by December 31, 2024. After several amendments—including those in December 2024 and May 2025—the milestone was gradually lowered.

The latest September 25, 2025 Amendment further reduces the net performance milestone to $1,785,625, with a new deadline of September 30, 2026. This milestone can be met through various funding sources, including equity, grants, licensing fees, or loans. Once achieved, Section 12 of the APA, which governs this performance requirement, will expire.

The adjustment reflects BioVaxys’ ongoing efforts to make the acquisition of the DPX™ platform more achievable while providing the company additional runway to secure the necessary funding.

Implications
By lowering the milestone, BioVaxys increases its flexibility to finance the platform acquisition and focus on the development of DPX™-based immunotherapies. For investors, it signals the company’s pragmatic approach to balancing capital requirements with operational timelines.